通过入组标准审视英国膀胱癌与头颈癌肿瘤试验组合的包容性:一项范围综述
该范围综述纳入2013至2023年间在英国招募受试者的膀胱癌或头颈癌多中心干预性II期和III期试验,共38项膀胱癌和30项头颈癌试验。常见排除标准涉及妊娠、体能状态、HIV状态和认知能力,可能不成比例地影响NIHR-INCLUDE指南提出的可能服务不足群体。作者建议申办者和试验者在制定入组标准时考虑如何安全地纳入可能代表性不足的群体。
要点
- 共纳入68项英国膀胱癌或头颈癌多中心干预性II期和III期试验。
- 常见排除标准涉及妊娠、体能状态、HIV状态和认知能力,可能不成比例排除服务不足群体。
- 作者建议申办者和试验者在制定入组标准时考虑安全纳入可能代表性不足的群体。
核心结论
- 本综述强调了可能不成比例地将服务不足群体排除在英国膀胱癌和头颈癌肿瘤试验之外的常见排除标准。
- 为促进肿瘤试验的可及性,申办者和试验者应考虑在制定入组标准时如何安全地纳入可能代表性不足的群体。
研究设计与样本
- 本范围综述纳入2013年至2023年间在英国招募受试者的膀胱癌或头颈癌多中心干预性II期和III期试验。
- 试验通过检索ClinicalTrials.gov、国际标准随机对照试验编号(ISRCTN)注册库和国家健康与护理研究所临床试验组合管理系统(NIHR CPMS) identified。
- 对试验的入组标准进行分类并叙述性分析,使用Fisher精确检验将试验参数(招募期、资助类型和是否为研究用药品(IMP))与常见排除标准进行交叉制表。
主要发现
- 38项膀胱癌试验和30项头颈癌试验符合选择标准。
- 68项试验中28项(41%)为非商业申办者。
- 68项试验中56项(82%)为研究用药品试验。
- 68项试验中41项(60%)为产业资助。
- 68项试验中51项(75%)针对局部晚期、转移性或复发性疾病。
关键数值与推荐
- 与妊娠、体能状态、HIV状态和认知能力相关的常见排除标准可能不成比例地影响NIHR-INCLUDE指南提出的一些服务不足群体。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In clinical trials, eligibility criteria define a population who may benefit from the intervention without incurring undue safety risks. Despite their value, overly stringent eligibility criteria may pose barriers to inclusive recruitment. They may disproportionately exclude groups of people more likely to be diagnosed at later cancer stages, or have specific co-morbidities which can be associated with socio-demographic or ethnic background. The National Institute for Health and Care Research Innovations in Clinical Trial Design and Delivery for the Under-served (NIHR-INCLUDE) guidance highlighted several groups of people who may be underserved by clinical research. The aim of this review was to assess eligibility criteria in bladder and head and neck oncology trials and consider their potential impact on potentially underserved groups. METHODS: This scoping review included multi-centre, interventional, phase II and III trials in bladder or head and neck cancer, which recruited UK participants between 2013 and 2023. Trials were identified via searches of ClinicalTrials.gov, the International Standard Randomised Controlled Trial Number (ISRCTN) registry, and NIHR Clinical Portfolio Management System (CPMS). Trials' eligibility criteria were categorised and analysed narratively. Trial parameters (recruitment period, funding type, and whether they were of investigational medicinal products (IMPs)) were cross-tabulated with common exclusion criteria using Fisher's exact test. RESULTS: Thirty-eight bladder and 30 head and neck cancer trials met the selection criteria. Twenty-eight out of 68 (41%) had non-commercial sponsors. Fifty-six out of 68 (82%) were of IMPs. Forty-one out of 68 (60%) were industry-funded. Fifty-one out of 68 (75%) were for locally advanced, metastatic, or recurrent disease. Common exclusion criteria relating to pregnancy, performance status, HIV status, and cognitive ability may disproportionately impact some underserved groups suggested by the NIHR-INCLUDE guidance. CONCLUSIONS: This review highlights common exclusion criteria which may disproportionately exclude underserved groups from UK bladder and head and neck oncology trials. To facilitate accessibility to oncology trials, sponsors and triallists should consider how potentially underrepresented groups may be safely included during development of eligibility criteria.
引用
- Synesi G, Lewis R, Kilburn L, et al. Reviewing inclusivity of the UK bladder and head and neck oncology trial portfolio through eligibility criteria: a scoping review. Trials. 2026. PMID: 41508127. doi:10.1186/s13063-026-09424-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。